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Abstract
Background
The interaction between tuberculosis and HIV-infected infection is well known and is responsible for the increase in the 
incidence of tuberculosis (TB) in sub-Saharan Africa over the last decade. This places a considerable extra burden on 
health services. The Brooklyn Hospital for Chest Diseases (BCH) is a non-acute TB hospital for the City of Cape Town, 
South Africa. The hospital has 60 children’s beds and approximately 140 paediatric admissions annually. This study, 
undertaken before the availability of antiretroviral drugs in the public sector in South Africa, documents the occurrence 
of nosocomial infections in HIV-infected and HIV-uninfected children at BCH.
Method
This retrospective case-control study evaluated the occurrence of nosocomial infections in (HIV)-infected children and 
age- and time of admission-matched HIV-uninfected children admitted to the BCH, Cape Town, South Africa between 
July 1999 and December 2001 for the treatment of tuberculosis (TB). 
Results
Forty-seven HIV-infected children (mean age 40 months) and 47 HIV-uninfected children (mean age 41 months) were 
studied. The HIV-infected children, who were not receiving antiretroviral therapy because it was not yet available in 
the public sector, experienced 109 episodes of nosocomial infections compared to 22 episodes amongst those not 
infected with HIV (p = 0.001). Twenty-five nosocomial infections (23%) among the HIV-infected children, but only 
two (9%) among the HIV-uninfected children, were serious enough to require transfer to a tertiary care hospital for 
management. Pneumonia was the commonest nosocomial infection and occurred in 26 (56%) HIV-infected patients, of 
whom three died, but in only four (9%) HIV-uninfected children, none of whom died. An outbreak of varicella affected 
10 HIV-infected (21%) and 9 HIV-uninfected children (19%). One HIV-infected child died of varicella pneumonia. Other 
common nosocomial infections encountered in HIV-infected and HIV-uninfected children respectively were upper 
respiratory tract infections (pharyngitis, tonsillitis or rhinitis) affecting 21 and four, otitis media in five and one, oral 
candidiasis in seven and zero, urinary tract infection in four and one and acute gastroenteritis in five and zero children. 
Five HIV-infected children (11%) died and four of the deaths were known to be due to nosocomial infection; only one 
HIV-uninfected child died from severe miliary TB. 
Conclusion
Nosocomial infections occurring in HIV-infected children are a serious cause of morbidity and mortality in children 
hospitalised for the treatment of tuberculosis. Their impact could be reduced by the earlier introduction of antiretroviral 
treatment and by immunisation against certain of the infecting agents. Post-exposure prophylaxis for varicella could 
prevent or alleviate disease.
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Introduction
The interaction between tuberculosis 
and human immunodeficiency virus 
(HIV) infection is well known and is 
responsible for the inordinate increase 
in the incidence of tuberculosis (TB) 
in sub-Saharan Africa over the last de-
cade.1 This epidemic affects both adult 
and childhood tuberculosis and places 
a considerable extra burden on health 
services. The Brooklyn Hospital for 
Chest Diseases (BCH) is a secondary 
level non-acute hospital that serves as 
the regional TB referral hospital for the 
Cape Town Metropole, as well as for 
complicated cases from further afield 
in the Western Cape Province. The 
hospital admits patients with severe or 
complicated disease, or whose social 
circumstances preclude community-
based, directly-observed therapy, short 
course (DOTS). BCH has two paediatric 
wards; one for children aged zero to 
five years with 40 beds, and the other 
for children aged six to 12 years with 20 
beds. There are approximately 140 pae-
diatric admissions annually. This study, 
undertaken before the ready availabil-
ity of antiretroviral drugs in the public 
sector in South Africa, documents the 
occurrence of nosocomial infections in 
HIV-infected and HIV-uninfected chil-
dren at BCH.
Methods
This is a retrospective case-control 
study of children admitted to BCH from 
July 1999 to December 2001 who had 
their HIV status determined. Patient data 
were recovered from a prospectively-
compiled patient register and hospital 
records. Each HIV-infected child was 
age-matched with an HIV-uninfected 
child admitted over the same period. 
In the case of infants aged zero to 12 
months, controls were within two months 
of age of the HIV-infected child, for chil-
dren aged one to two years, within three 
months, for children aged two to five 
years, within one year, and for children 
aged six to 12 years, within 18 months 
of the HIV-infected child. The negative 
controls were selected by choosing the 
closest age-matched patient admitted 
within four months of each HIV-infected 
patient. 
The HIV status of the children was 
determined after pre-test counselling 
and with written informed consent from 
the child’s legal guardian. Two HIV 
enzyme-linked immunosorbent assays 
(ELISAs) were performed in children 
older than 15 months, and a positive 
ELISA together with a positive poly-
merase chain reaction or detection of 
the p24 antigen was required in children 
younger than 15 months to confirm HIV 
infection. 
Demographic details, clinical fea-
tures, the results of diagnostic investi-
gations and the outcome at the time of 
discharge for each child were noted.
A diagnosis of confirmed TB was ac-
cepted in the presence of a culture of 
Mycobacterium tuberculosis from gastric 
aspirate, sputum, cerebrospinal fluid 
(CSF) or any biopsy specimen or the 
finding of acid-fast bacilli on microsco-
py of any specimen if accompanied by 
a positive Mantoux tuberculin skin test 
(TST), or a chest radiograph compatible 
with childhood tuberculosis, or a his-
tory of recent close household contact 
with an adult with sputum microscopy 
smear-positive pulmonary TB.
 Probable TB was diagnosed in children 
with two or more of the following:
•  a positive TST (≥15 mm induration 
in HIV-uninfected; ≥5 mm in HIV-in-
fected) 
•  an abnormal chest radiograph show-
ing features of childhood TB (medi-
astinal adenopathy and/or a miliary 
picture responding to antituberculo-
sis treatment) 
•  close contact with an adult with spu-
tum microscopy smear-positive TB
•  a CSF picture suggestive of TB 
meningitis (TBM) (elevated protein 
of >0.5 g/l, reduced glucose (<2.2 
mmol/l) and a predominantly lympho-
cytic pleocytosis not exceeding 500 
cells/mm3) 
•  central nervous system imaging ab-
normalities suggesting TBM (basal 
meningitis, vasculitis, infarcts, hydro-
cephalus)
Treatment was in accordance with the 
recommendations of the South African 
TB Control Programme. Children with 
uncomplicated pulmonary TB received 
a six-month course of treatment consist-
ing of an intensive phase of isoniazid, 
rifampicin and pyrazinamide for two 
months, with ethambutol added in 
cases of microscopy smear-positive 
sputum, cavitation or extensive opacifi-
cation, followed by a continuation phase 
of isoniazid and rifampicin for four 
months. Patients with extra-pulmonary 
TB, including TBM and disseminated 
(miliary) TB, received isoniazid, rifam-
picin, pyrazinamide and ethionamide 
for six months. Patients with mono-resis-
tant or multidrug-resistant TB received 
regimens appropriate to their respective 
drug susceptibility results.
At the time of the study, antiretrovi-
ral therapy was not yet available in the 
public sector in South Africa. All HIV-in-
fected patients admitted to the study re-
ceived trimethoprim/sulphamethoxazole 
as prophylaxis for Pneumocystis jiroveci 
pneumonia (PCP).
Nosocomial infection was diagnosed 
primarily on clinical grounds and defined 
as infection not present or incubating on 
admission to BCH and presenting 72 
hours after hospitalisation in the case of 
bacterial infections, 96 hours in the case 
of viral respiratory tract infections, and 
21 days in the case of varicella. Nosoco-
mial infections acquired at the referring 
hospital were distinguished from those 
acquired at BCH; only the latter were 
considered for the study.
The effect of nosocomial infections 
was assessed in terms of the diagnostic 
evaluation required, the introduction of 
oral antibiotics at BCH (where no intra-
venous medication is administered), 
oral rehydration therapy, nasogastric 
feeds, need for transfer back to the re-
ferring or an appropriate hospital, and 
emergency treatment required before 
transfer to such hospitals (e.g. supple-
mental oxygen, intravenous antibiotics, 
or intensive care), prolongation of hospi-
talisation, or death.
Outcome definitions: Children were 
considered cured if repeat TB cultures 
were negative and/or all radiological 
and clinical signs had cleared. If re-
sidual changes were still evident either 
clinically (in the form of neurological def-
icits after TBM, or bony deformities after 
TB of bone, or clinical suggestion of 
bronchiectasis) or radiologically (chest 
radiograph not entirely clear, residual 
computed tomographic changes after 
TBM), they were classified as “cured 
with residual changes”. 
Children were considered improved 
if radiological and clinical improvement 
had occurred and they were discharged 
for further treatment elsewhere. Those 
with no radiological or clinical improve-
ment upon discharge for treatment con-
tinuation were classified as unchanged. 
Statistical analysis: Continuous vari-
ables are described as medians with 
lower and upper quartiles in parenthe-
sis. Categorical variables were com-
pared with the Chi squared test. The Wil-
coxon Matched Pairs Test was used to 
SA Fam Pract 2007:49(7)14 b
Original Research
compare paired data. A p value of less 
than 0.05 was considered significant. 
Analysis was performed using Statisti-
ca® version 6.1 (Statsoft, Inc.)
The study was approved by the In-
stitutional Review Board of the Faculty 
of Health Sciences, Stellenbosch Uni-
versity.
Results
During the 30 months of the study, 401 
children were admitted to BCH; the HIV 
status of 156 (38.9%) was evaluated and 
104 (66.7%) were HIV-uninfected and 
52 (33.3%) were HIV-infected. Hospital 
records for three HIV-infected patients 
were lost and no suitable age-matched 
controls were found for two HIV-infect-
ed children. The final study population 
was therefore 47 age-matched pairs of 
HIV-infected and HIV-uninfected chil-
dren. The demographic and diagnos-
tic characteristics and the growth eval-
uation of the children are summarised in 
Table I. The major differences between 
the groups lie in the significantly poor-
er response to tuberculin testing in the 
HIV-infected children and their anthro-
pometric findings. Height for age was 
significantly lower in HIV-infected chil-
dren, as was weight for age. Weight for 
height, however, did not differ signifi-
cantly. These anthropometric differenc-
es did not influence the TST results.
The reasons for inpatient treatment at 
BCH were not different between the two 
groups. In the HIV-infected and HIV-un-
infected children, the reasons for ad-
mission were severity of disease in 27 
(57.4%) and 34 (72.3%) cases, so-
cial reasons in seven (3.3%) and four 
(8.5%), and both severity of disease 
and social reasons in 13 (27.7%) and 
nine (19.1%) cases respectively. 
Of the HIV-infected patients, there 
were two (4.3%) patients in Centers for 
Disease Control and Prevention (CDC) 
category N, five (10.6%) in category 
A, eight (17.0%) in category B, and 
32 (68.1%) in category C.2 In 25 of the 
patients assigned to category C, extra-
pulmonary or disseminated TB was the 
only category C defining criterion. 
In 20 (42.6%) HIV-infected patients, 
the HIV status of the parents was 
documented, and in 18 they were also 
seropositive, implying vertical HIV trans-
mission. The two children of sero-nega-
tive parents both had a history of sexual 
abuse. 
The mean duration of hospitalisation 
for HIV-infected patients was 141 (106, 
193) days, and that for HIV-uninfected 
patients 160 (115, 187) days (p = 0.58).
Nosocomial infections
Fifty-three of the 94 (56.4%) children ex-
perienced 131 episodes of nosocomial 
infection; 109 (83%) episodes occurred 
in 37 HIV-infected children and 22 in 
16 HIV-uninfected children (p <0.001). 
HIV-infected children experienced a 
median of two (one, three) episodes of 
infection compared to a median of zero 
(zero, one) amongst HIV-uninfected 
children (p <0.001). Details of the infec-
tions experienced are summarised in 
Table II. 
Twenty-five of 109 (22.9%) episodes 
of infection in HIV-infected children re-
quired transfer to a secondary or tertiary 
care hospital, but only 2/22 (9.1%) epi-
sodes affecting HIV-uninfected children 
(p=0.254) required transfer. 
Pneumonia was the commonest nos-
ocomial infection in both HIV-infected 
and HIV-uninfected children and ac-
counted for 29 of 109 (26.6 %) episodes 
of infection amongst 26 HIV-infected 
patients. Thirteen of 26 (50.0%) of these 
patients required intravenous antibiotics 
and/or oxygen therapy and were trans-
ferred to secondary or tertiary hospitals. 
Three HIV-infected patients (11.5%) 
who developed pneumonia died: one 
with varicella pneumonia and two with 
suspected bacterial pneumonia. Four 
HIV-uninfected children had clinical and 
radiological signs of pneumonia. Two of 
these patients were transferred out, and 
the other two were managed at BCH 
with oral antibiotics. All four recovered.
Demographic and diagnostic features
HIV-infected 
 N = 47 (%)
HIV-uninfected 
N = 47 (%)
P value
Age (months) 39.9 (3.8–142.3) 40.55 (4.3–145.7) NS
Sex (males) 24 (51.1) 34 (72.3) NS
Culture of M. tuberculosis 27 (57.4) 32 (68.1) NS
AFB seen in sputum, gastric aspirate 
or on histology
16 (34.0) 16 (34.0) NS
Mantoux test (mm induration) Median 0, range 0-26 Median 16, range 0-27
 ≥15 mm 15 (31.9) 32 (68.1) p<0,001
 ≥5 mm (HIV-infected) 21 (44.7) -
  All positive Mantoux TST 21 (44.7) 32 (68.1) p=0.022
Radiology compatible with TB 40 (85.1) 47 (100) 0.012
Close household TB contact 28 (59.6) 23 (48.9) NS
Pulmonary TB 16 (34.0) 13 (27.7) NS
Extra-pulmonary TB 28 (59.6) 28 (59.6) NS
Pulmonary and extra-pulmonary TB 3 (6.4) 6 (12.8) NS
Confirmed TB 27 (57.4) 32 (68.1) NS
Probable TB 20 (42.6) 15 (31.9) NS
Growth evaluation Mean Z-score (SD)
 Height for age -2.84 (1.60) -2.09 (1.95) 0.018*
 Weight for age -1.89 (1.16) -1.31 (1.40) 0.018*
 Weight for height -0.15 (1.67) 0.065 (1.59) 0.547*
NS = not significant, AFB = acid-fast bacilli, TB = tuberculosis
* = T-test for dependent samples
Table I: Demographic and diagnostic features of HIV-infected and matched HIV-uninfected children
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Table II: Nosocomial infections diagnosed in HIV-infected and matched HIV-uninfected children 
* Some diagnoses occurred more than once in the same child 
Diagnosis* HIV-infectedN = 47
HIV-uninfected
N = 47
Lower respiratory tract infections   
 Pneumonia 29 4
 Respiratory tract infection with lower airways  
obstruction 3 1
 Exacerbation of bronchiectasis 2 0
 Empyaema 1 0
 Laryngotracheobronchitis 1 0
Upper respiratory tract   
 Pharyngitis/tonsillitis/rhinitis 21 4
 Otorrhoea 3 3
 Acute otitis media 5 1
Oral cavity   
 Candidiasis 9 0
 Herpes stomatitis 7 1
Miscellaneous   
 Conjunctivitis 4 1
 Skin infections 7 0
 Varicella zoster (shingles) 1 0
 Urinary tract infection 4 1
Central nervous system   
 Bacterial meningitis 2 0
 Aseptic meningitis 1 0
Gastrointestinal tract   
 Acute gastroenteritis 5 0
 Protracted diarrhoea 1 0
 Spontaneous peritonitis 1 0
Fever without focus   
 Suspected bacterial septicaemia 1 0
 Suspected viraemia 1 0
Varicella (chickenpox) 10 9
An outbreak of varicella (chickenpox) 
occurred in the period under review 
and 18 (19.1%) children experienced 
19 episodes of varicella. This was the 
second commonest nosocomial infec-
tion experienced. Ten of the episodes 
occurred in nine HIV-infected children 
(including one CDC category C patient 
who had the illness twice, two months 
apart), and nine occurred in HIV-un-
infected children. All 10 episodes in 
HIV-infected children were treated with 
acyclovir, as were four episodes in the 
HIV-uninfected children. Two children 
(both HIV-infected) developed varicella 
pneumonia, one of whom died. One of 
the HIV-infected children developed 
herpes zoster four months after vari-
cella. 
Other serious nosocomial infections 
that required transfer to secondary or 
tertiary hospitals were:
•  empyaema – in an HIV-infected child
•  laryngotracheobronchitis/croup in an 
HIV-infected child 
•  persistent diarrhoea in an HIV-in-
fected child who had more than three 
loose stools a day for 17 days before 
developing signs of dehydration, 
despite oral rehydration therapy and 
nasogastric nutrition 
•  pyelonephritis in two HIV-infected 
children requiring intravenous antibi-
otics 
•  primary peritonitis in an HIV-infected 
child 
•  meningitis in two HIV-infected chil-
dren, one with pneumococcal menin-
gitis and one with aseptic meningitis
The clinical impact of nosocomial 
infection is summarised in Table III. 
Nosocomial infections led to transfers to 
other hospitals, special investigations or 
additional treatment, but in no child was 
hospital stay in BCH prolonged. 
The outcome of the TB treatment is sum-
marised in Table IV. Six (6.4%) children 
died; five of these were infected with 
HIV, four had category C disease and 
one had category A disease. The age 
at death ranged from four to 67 months. 
Of the five HIV-infected children, three 
died of pneumonia (one varicella pneu-
monia), one of septicaemia with an 
unknown primary focus and one child 
(category C disease) died unexpectedly 
on weekend home leave and the cause 
of death was unknown. A five-month-old 
HIV-uninfected infant died from severe 
miliary TB. In four of the five HIV-infected 
children who died, the deaths were 
caused by nosocomial infections.
Effect of nosocomial infection HIV-infected HIV-uninfected
Death 4 0
Transfer to secondary or tertiary hospital 25 2
Laboratory or radiological investigation at BCH 35 6
Introduction of oral antibiotics/acyclovir 71 11
Oral rehydration 8 1
Nasogastric feeds 9 1
Oxygen therapy** 13 2
Intravenous fluids or antibiotics† 18 3
Topical therapy 21 5
Prolongation of hospitalisation 0 0
No effect 0 0
Table III: The impact that nosocomial infections had on the children *
* some nosocomial infections had more than one effect
† these patients were transferred out after being stabilised
Table IV: Outcome of children hospitalised for tuberculosis at Brooklyn Chest Hospital 
Outcome of tuberculosis after 
hospitalisation
HIV-infected
N = 47 (%)
HIV-uninfected
N = 47 (%) P value
Cured 10 (21.3) 21 (44.7) 0.028
Cured with residual changes 11 (23.4) 14 (29.8) NS
Improved, transferred out to 
complete treatment elsewhere 17 (36.2) 11 (23.4) NS
Condition unchanged, discharged to 
complete treatment elsewhere 4 (8.5) 0 NS
Died   5 (10.64%) 1 (2.13%) NS
Discussion
TB is a major public health problem in 
South Africa, especially in the Western 
Cape, and the HIV pandemic has led 
to an escalation of this problem. In 
1997/1998, TB prevalence in the West-
ern Cape was 614/100 000 (all ages), 
while the national figure was 419/100 
000.3 The HIV prevalence at Western 
Cape public health antenatal clinics 
in October 2000 was 8.7% compared 
with 24.5% nationally, although 16.8% 
of TB cases in the Western Cape were 
co-infected with HIV compared to 32.8% 
nationally.4
This study examined the contribution 
of nosocomial infections to in-hospital 
morbidity and mortality in HIV-infected 
and HIV-uninfected children hospital-
ised for TB in a Western Cape TB referral 
hospital. The most striking finding is the 
significantly larger number of HIV-infect-
ed children who developed nosocomial 
infections (37; 78.7% vs. 16; 34.0%), 
and the significantly larger number of 
infectious episodes per HIV-infected 
child. The nosocomial infections in HIV-
infected children were often severe, with 
25 (23%) episodes resulting in transfer 
of the children to secondary or tertiary 
hospitals, compared with only two (9%) 
in the HIV-uninfected children. The CDC 
category did not influence the number of 
nosocomial infections. 
Pneumonia was the commonest noso-
comial infection in HIV-infected children 
and contributed significantly to morbid-
ity and mortality in this group; 13 (50%) 
of the HIV-infected patients who devel-
oped pneumonia required intravenous 
antibiotics and/or oxygen therapy and 
transfer to other hospitals, and three 
died. Other South African studies also 
found pneumonia to be the common-
est nosocomial infection in HIV-infected 
children with TB,5 and the commonest 
cause of illness and mortality in HIV-in-
fected children in general.6 
Because diagnoses at BCH were pri-
marily clinical and radiological, the ae-
tiological agents in most of the cas-
es of pneumonia are unfortunately un-
known. All HIV-infected patients re-
ceived trimethoprim/sulphamethoxazole 
as prophylaxis against PCP. The conju-
gate vaccine against Haemophilus influ-
enzae type b became part of the nation-
al immunisation program for South Afri-
can children in 1998, but children older 
than one year during this study period 
were probably not immunised against 
Haemophilus influenzae type b. 
Streptococcus pneumoniae, Haemophi-
lus influenzae and other gram-nega-
tive bacteria are known to be frequent 
causes of bacterial pneumonia in HIV-
infected children.6 Empirical therapy for 
children with pneumonia in hospitals 
in Cape Town includes cover against 
Gram-positive and Gram-negative or-
ganisms, with intravenous trimethoprim/
sulphamethoxazole being added in the 
case of infants younger than one year 
old with positive or unknown HIV status 
and clinical suspicion of PCP.
Varicella was the most common 
nosocomial infection in HIV-uninfected 
children and the third most common in 
HIV-infected children. All HIV-infected 
children who developed varicella were 
treated with oral acyclovir. Of the nine 
HIV-infected children who developed 
varicella, four (44.4%) developed com-
plications during the period of hospi-
talisation, compared with none of the 
HIV-uninfected children. Pneumonia 
occurred in two patients, one of whom 
died, recurrence of varicella occurred in 
one child and varicella zoster occurred 
in another. No episodes of bacterial 
super-infection of skin lesions were re-
corded in either the HIV-infected or the 
HIV-uninfected patients and no persis-
tence of varicella lesions beyond one 
month after onset was recorded in the 
HIV-infected group. At least one of the 
episodes of varicella developed by an 
HIV-infected child in BCH was a recur-
rence, since the child was known to be 
varicella IgG positive at admission. 
Other studies have shown very high 
incidences of recurrence (either recur-
rent varicella or of zoster) in HIV-infected 
children who developed varicella before 
the era of antiretroviral therapy. A study 
from Romania showed that, in the case 
of HIV-infected children who were fol-
lowed from their primary episodes, 45% 
had a recurrence within 24 months.7 
Factors determining whether a recurrent 
episode will be varicella or zoster are 
not known. Recurrences may be due to 
reactivation, although re-infection often 
cannot be excluded.
The Romanian study also reported 
high rates of complications from vari-
cella zoster virus (VZV) infections in 
HIV-infected children not receiving an-
tiretroviral therapy. Of 38 cases of vari-
cella, 40% developed complications, in-
cluding skin super-infection, pneumonia 
and thrombocytopaenia, and two (5%) 
children died from respiratory failure. 
Most of these children had not received 
acyclovir.7
The overall low incidence of gastro-
enteritis in our study population is strik-
ing; only five children (5.3%) developed 
acute gastroenteritis (five out of 131 
nosocomial infection episodes). 
HIV-infected children not only suf-
fered many more severe infections 
than their uninfected counterparts, but 
they also suffered many more minor 
illnesses, such as skin infections and 
upper respiratory tract infections, which 
may affect the children’s quality of life 
and place a considerable extra burden 
on both staff and resources, as detailed 
in Table IV.
As is well described, a significantly low-
er percentage of HIV-infected children 
had a reactive Mantoux test compared 
to HIV-uninfected children. The num-
bers of positive cultures for M. tubercu-
losis and/or acid-fast bacilli seen in spu-
tum, gastric washings, CSF or tissue on 
direct microscopy, and history of house-
hold TB contact, however, did not differ 
significantly between the groups.
Thirty-two (68%) of the HIV-infected 
children fell into CDC clinical catego-
ry C. However, in 25 of these patients 
(78%), extra-pulmonary or disseminat-
ed TB was the only CDC category C-
defining condition present. Since HIV-
uninfected patients in this sample had 
a similar incidence of extra-pulmonary 
TB, it is debatable whether this per se 
denotes category C HIV disease in all 
these patients. The lack of supporting 
data on CD4 cell counts is a limitation 
of the study.
TB accelerates HIV disease progres-
sion,8 and it is not surprising that other 
South African studies have also docu-
mented a poorer treatment-response 
and a higher mortality rate due to non-
TB causes amongst HIV-infected chil-
dren with TB.5,9,10 In this study, the cure 
rate was significantly lower amongst the 
HIV-infected patients than the uninfect-
ed patients, but although more deaths 
occurred in the HIV-infected children, 
this difference was not statistically sig-
nificant.
With the recent introduction of an-
tiretroviral therapy in the public sector 
in South Africa, it may be expected that 
the mortality and morbidity of HIV-infect-
ed children on TB treatment will be re-
duced. The advent of highly active an-
tiretroviral therapy has significantly re-
duced the incidence of and mortality 
from pneumonia and other opportunis-
tic infections in the developed world.6 In 
many children, however, it is the diag-
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nosis of TB that precipitates testing for 
HIV-infection and several months will 
usually pass before antiretroviral treat-
ment is started and becomes fully effec-
tive, leaving the children susceptible to 
nosocomial infections, as described in 
this paper.
The administration of the conjugate 
pneumococcal vaccine could be con-
sidered for those HIV-infected children 
being treated for tuberculosis. The vac-
cine is not as immunogenic in HIV-in-
fected children as in their HIV-uninfect-
ed counterparts, but given their burden 
of pneumococcal disease it might still 
make a significant difference.6
Hospital outbreaks of varicella are 
common. Vaccination against VZV has 
been shown to be safe and immunogen-
ic in asymptomatic or minimally symp-
tomatic HIV-infected children (CDC clin-
ical categories N1 and A1) and is rec-
ommended for such children.11,12 A re-
cent study has also shown that it may 
be immunogenic in HIV-infected chil-
dren who have developed symptoms 
or have a CD4 cell percentage of more 
than 15% at the time of immunisation.13 
Vaccination at this stage also signifi-
cantly reduces the chances of reacti-
vation compared to allowing the child 
to develop chickenpox at a later stage, 
when immunity has further deteriorated. 
The varicella vaccine is contraindicated 
in T-cell immunocompromised children, 
including those on steroid treatment (≥2 
mg/kg prednisone), as is given to chil-
dren with TBM. Most of our HIV-infect-
ed patients were CDC category C at ad-
mission with unknown CD4 cell counts, 
which means that the efficacy of varicel-
la-zoster vaccination at admission would 
be debatable. However, a recent study 
showed the vaccine to be safe and im-
munogenic in HIV-infected patients at 
any stage of disease who are on anti-
retroviral therapy and have a CD4 count 
of >700 cells/µl.14 Passive immunisation 
against VZV at admission may not be ef-
fective, as it has been shown that break-
through disease can occur due to a lon-
ger incubation period of VZV in HIV-in-
fected children.15 Cost is a constraint to 
the general immunisation of HIV-infect-
ed children against VZV at the time of 
HIV diagnosis.
For post-exposure prophylaxis, vac-
cination should be given within 72 hours 
of exposure, and this could prevent or 
alleviate illness in the majority of chil-
dren.16 For children at risk of severe dis-
ease, including HIV-infected children, 
other T-cell immunocompromised chil-
dren and premature neonates, varicel-
la zoster immunoglobulin (VZIG) can 
be given within 96 hours post expo-
sure at a dose of 1.25 ml (one vial)/10 kg 
body weight (minimum dose) to a max-
imum of 6.25 ml (five vials).12 Some tri-
als in healthy children have shown acy-
clovir (30–40 mg/kg/day in three to four 
divided doses orally), given at time five 
to seven days post exposure for five to 
seven days’ duration, to be effective in 
preventing or modifying varicella. Stud-
ies on the effectiveness of acyclovir in 
post-exposure prophylaxis in immuno-
compromised children are sparse, but it 
has been shown to prevent the develop-
ment of disease in premature babies17 
and, as an adjunct to VZIG, in children 
with renal disease receiving steroids.18 
High-dose acyclovir could therefore be 
useful in preventing or alleviating vari-
cella disease in HIV-infected or other im-
munocompromised patients, especially 
if the vaccine is contraindicated.16
This study has several limitations, of 
which the retrospective nature of the 
study is the most important. CD4 counts 
were not available and thus the exact 
CDC category of HIV disease was dif-
ficult to determine. BCH is also a non-
acute hospital and few special investi-
gations can be done, which means that 
the identification of the etiologic agents 
of nosocomial infections was not possi-
ble in most infections. 
In summary, HIV-infected children 
admitted to hospital for the manage-
ment of TB experienced considerably 
more morbidity and mortality due to nos-
ocomial infection than HIV-uninfected 
children. The most common nosocomi-
al infection and cause of death in HIV-in-
fected children was pneumonia, proba-
bly due to other organisms and not due 
to TB. Varicella occurred very common-
ly during this period and caused seri-
ous illness, a high rate of complications 
and one death. Such outbreaks can be 
largely prevented. HIV-infected children 
also suffered significantly more minor ill-
nesses. 
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